The Pharma Data
SEPTEMBER 10, 2021
” Researchers will present results from several studies in advanced Parkinson’s disease, including long-term, real-world data for DUODOPA ® (levodopa-carbidopa intestinal gel), as well as additional data on the long-term, real-world use of BOTOX ® (onabotulinumtoxinA) in patients with spasticity and cervical dystonia.
The Pharma Data
APRIL 7, 2021
” Researchers will present data from several studies on migraine, including new findings on atogepant, AbbVie’s investigational preventive treatment of migraine in adults who meet criteria for episodic migraine as well as results evaluating the efficacy and safety of BOTOX ® (onabotulinumtoxinA) and UBRELVY ® (ubrogepant).
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
NOVEMBER 18, 2020
UK cost-effectiveness agency NICE has said that Eli Lilly’s Emgality can be made available through the NHS for migraine prevention, the second drug in the CGRP inhibitor class to achieve that milestone. Aimovig is said to be the most prescribed anti-CGRP drug worldwide with more than 480,000 patients prescribed the drug worldwide.
pharmaphorum
NOVEMBER 4, 2020
Novartis’ injectable migraine prevention antibody Aimovig has been shown to be more effective than topiramate – a go-to oral therapy for people with chronic migraine – in a head-to-head trial. Both drugs can take up to three months for their effect on migraine prevention to fully kick in. Photo by Carolina Heza on Unsplash.
pharmaphorum
NOVEMBER 18, 2020
UK cost-effectiveness agency NICE has said that Eli Lilly’s Emgality can be made available through the NHS for migraine prevention, the second drug in the CGRP inhibitor class to achieve that milestone. Aimovig is said to be the most prescribed anti-CGRP drug worldwide with more than 480,000 patients prescribed the drug worldwide.
The Pharma Data
SEPTEMBER 8, 2021
–Results from a post-hoc analysis of the Phase 3 PREEMPT trials evaluate the use of BOTOX® (onabotulinumtoxinA) for chronic migraine –These data further demonstrate AbbVie’s commitment to harnessing and sharing innovative science and working to advance treatment options for people with migraine across the migraine spectrum.
The Pharma Data
APRIL 30, 2021
Global Botox Cosmetic net revenues were $477 million , an increase of 44.7 Global Botox Therapeutic net revenues were $532 million , an increase of 7.0 The updated Prescription Drug User Fee Act (PDUFA) action dates have been extended three months to late 2Q 2021 for PsA and early 3Q 2021 for AD. Recent Events.
Expert insights. Personalized for you.
52 
Let's personalize your content